[1] Bruix J,Sherman M.Management of hepatocellular carcinoma: An update .Hepatology, 2011,53:1020-1022.
[2] 宿敬存,赵卫,胡继红,等.TACE联合RFA及自体细胞因子诱导的杀伤细胞肝动脉灌注治疗 原发性肝癌的临床研究.介入放射学杂志,2017,26:30-35.
[3] 郝锐,郑雪松,张莲莲,等.5种血清标志物在肝癌诊断中的应用价值.中国地方病防治杂志, 2018,33:125-127.
[4] Montalbano M,Rastellini C,Wang X F,et al.Sa1843 Cellular localization and function of Glypican3 (Gpc3) in human primary culture of hepatocellular carcinoma (HCC) and Pr e-HCC cells. Gastroenterology,2015,148:S-1022.
[5] 中国抗癌协会肝癌专业委员会,中华医学会肝病学分会肝癌学组,中国抗癌协会病理专业 委员会,等.原发性肝癌规范化病理诊断指南(2015年版).中华肝胆外科杂志,2015,23: 321-327.
[6] Lencioni R,Llovet J M.Modified RECIST (mRECIST) assessment for hepatocellular car cinoma..Semin Liver Dis,2010,30:052-060.
[7] Yu JP, Xu XG, Ma RJ,et al. Development of a clinical chemiluminescent immunoass ay for serum GPC3 and simulta-neous measurements alone with AFP and CK19 in diag nosis of hepatocellular carcinoma.J Clinl Lab Anal,2015,29:85-93.
[8] 王晴晴,庄林,雷华,等.血清DCP、AFP、AFU在原发性肝癌临床诊断中的价值.肝脏,2 017,22:129-131.
[9] 胡友明,张娟安,刘军,等.AFP、AFU、GPC3及GP73联合检测对原发性肝癌的诊断意义. 实用癌症杂志,2017,32:375-388.
[10] 马洁,汪顺才,朱梦琪,等.检测 GPC3和 GP73两种方法的比较及与临床的相关性.安徽 医科大学学报,2015,50:707-710.
[11] 李伟男,杨刚,李敬东,等.术前经肝动脉化疗栓塞联合肝切除治疗原发性肝癌疗效的Meta 分析.中华普通外科杂志,2017,32:61-63.
[12] Lv N , Kong Y , Mu L , et al. Effect of perioperative parecoxib sodium on postoper ative pain control for transcatheter arterial chemoembolization for inoperable hepatocellu lar carcinoma: a prospective randomized trial.Eur Radiol,2016,26:3492-34 99. |
